Lars Thomsen was headhunted to AstraZeneca in 1998/1999 for working in a new Target Discovery group with the aim of identifying novel targets in existing and emerging diseases. The work involved advanced trangenetics using mice in which individual genes have been inactivated “knocked-out” from the mice and from which one study the effect of such genes in relation to normal and pathophysiology at the molecular level.